Overview

A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Status:
Recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety of FCX-007, evaluate C7 expression and the presence of anchoring fibrils resulting from FCX-007 and to analyze wound healing as a result of FCX-007 administration in subjects with RDEB.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Fibrocell Technologies, Inc.
Collaborator:
Intrexon Corporation